Targeted delivery using aptamers

April 11th, 2019|Categories: Past Webinars|

Presenter: Donald H. Burke/David Porciani, University of Missouri, USA Date: July 25, 2019 Description: Currently, effective cell-targeted delivery tools for oligonucleotide therapeutics are limited. Aptamers that internalize into target cells have been shown to deliver a wide variety of nucleic acid therapeutics, from siRNAs ...

An Overview of Chemical Modifications to CRISPR RNA

February 13th, 2019|Categories: Past Webinars|

Presenter: Keith Gagnon, Southern Illinois University, USA Date: March 21, 2019 Description: CRISPR-based genome editing has emerged as an exciting technology for biomedical and therapeutic applications. Since 2015, a number of studies have explored the effects of chemically modifying the guide RNA components of ...

Guidelines for Experiments using Antisense Oligonucleotides and Double-Stranded RNAs

November 15th, 2018|Categories: Past Webinars|

Presenter: David Corey PhD, University of Texas, USA Date: 6 December 2018 Description: After decades of research and development, synthetic nucleic acids are beginning to enjoy significant success in the clinic. Approved drugs have increased interest in the field and many basic research studies ...

Oligonucleotide Therapeutics: Technology Evolution for Clinically Relevant Tissue Delivery

June 22nd, 2018|Categories: Past Webinars|

Presenter: Anastasia Khvorova, PhD, RNA Therapeutics Institute, University of Massachusetts Medical School Date: 10 September 2018 Description: A decade of progress in oligonucleotide chemistry and formulation development has resulted in several compounds, both siRNAs and antisense, demonstrating robust clinical activity. Based on sequence, these ...

Design of Exon Skipping Oligonucleotides

January 25th, 2018|Categories: Past Webinars|

Presenter: Annemieke Aartsma-Rus, PhD, Leiden University Medical Center Date: 20 February 2018 Description: Antisense-mediated splicing modulation utilizes antisense oligonucleotides (ASOs) to manipulate the splicing by sterically blocking the binding of splicing factors to pre-mRNA transcripts. While in industry often oligo walks are used to ...

Go to Top